Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Toffoli

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
The Pharmacogenomics Journal|March 18, 2015
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patientsS Chen, I Laverdiere, A Tourancheau, et al.
Journal of Mass Spectrometry : JMS|March 3, 2017
Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasmaS D'Aronco, M Dall'Armi, S Crotti, et al.
Critical Care Medicine|March 13, 1999
Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unitM De Cicco, F Macor, I Robieux, et al.
The Pharmacogenomics Journal|April 7, 2010
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapyE Cecchin, M Agostini, S Pucciarelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 15, 2017
SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorderM Toffoli, E Dreussi, E Cecchin, et al.
The Pharmacogenomics Journal|October 22, 2014
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatinE Cecchin, G Perrone, S Nobili, et al.
The Pharmacogenomics Journal|April 9, 2014
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisM M Dias, J-P Pignon, C S Karapetis, et al.
American Journal of Epidemiology|October 23, 2009
Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC reviewE Taioli, M A Garza, Y O Ahn, et al.
Clinical Pharmacology and Therapeutics|September 22, 2018
CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics ConsortiumC H van der Wouden, A Cambon-Thomsen, E Cecchin, et al.
Clinical Pharmacology and Therapeutics|December 28, 2016
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics ConsortiumC H van der Wouden, A Cambon-Thomsen, E Cecchin, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
The Pharmacogenomics Journal|March 18, 2015
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patientsS Chen, I Laverdiere, A Tourancheau, et al.
Journal of Mass Spectrometry : JMS|March 3, 2017
Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasmaS D'Aronco, M Dall'Armi, S Crotti, et al.
Critical Care Medicine|March 13, 1999
Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unitM De Cicco, F Macor, I Robieux, et al.
The Pharmacogenomics Journal|April 7, 2010
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapyE Cecchin, M Agostini, S Pucciarelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 15, 2017
SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorderM Toffoli, E Dreussi, E Cecchin, et al.
The Pharmacogenomics Journal|October 22, 2014
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatinE Cecchin, G Perrone, S Nobili, et al.
The Pharmacogenomics Journal|April 9, 2014
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisM M Dias, J-P Pignon, C S Karapetis, et al.
American Journal of Epidemiology|October 23, 2009
Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC reviewE Taioli, M A Garza, Y O Ahn, et al.
Clinical Pharmacology and Therapeutics|September 22, 2018
CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics ConsortiumC H van der Wouden, A Cambon-Thomsen, E Cecchin, et al.
Clinical Pharmacology and Therapeutics|December 28, 2016
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics ConsortiumC H van der Wouden, A Cambon-Thomsen, E Cecchin, et al.
Pageof 9